Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
Holding BCRX?
Track your performance easily
BCRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.03 - $8.88
Previous Close$7.96
Volume1.92M
Average Volume (3M)2.58M
Market Cap
$1.65B
Enterprise Value$1.70B
Total Cash (Recent Filing)$272.03M
Total Debt (Recent Filing)$327.01M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Oct 30, 2024EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding206,885,936
10 Day Avg. Volume1,466,318
30 Day Avg. Volume2,584,987
Standard Deviation0.22
R-Squared0.19
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-3.54
Price to Sales (P/S)4.31
Price to Cash Flow (P/CF)-301.00
P/FCF Ratio17.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.45
Enterprise Value/Gross Profit5.21
Enterprise Value/Ebitda-70.59
Forecast
1Y Price Target
$15.33Price Target Upside88.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
BioCryst News
Bulls Say, Bears Say
Bulls Say
Drug Development And Sales PotentialBioCryst's initiation of a proof-of-concept trial for its oral factor D inhibitor in PNH patients highlights the company's commitment to addressing complement-mediated diseases and signals potential for significant growth in the drug's value.
Financial Performance And Market ConfidenceAnalyst maintains a Market Outperform rating on BioCryst, bolstered by strong Orladeyo sales growth and management's guidance towards profitability, painting a promising picture for investors.
Pipeline Expansion And Market OpportunityBioCryst's development of new preclinical candidates and the strategic expansion of Orladeyo's label for pediatric use underscore the company's potential for sustained growth and market expansion.
Bears Say
Analyst AdjustmentAnalyst has lowered the price target for BioCryst, reflecting adjustments in their financial valuation.
Earnings Guidance2024 guidance of $380-400M is slightly below consensus of $404M.
Sales ForecastManagement does not expect much progress on the Medicare population in 2024 affecting Orladeyo sales.
---
Ownership Overview
13.70% Insiders
20.70% Mutual Funds
55.50% Other Institutional Investors
10.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCRX FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was $4.03 and its highest was $8.88 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Currently, no data Available
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is Oct 30, 2024 which is in 40 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on Aug 05, 2024. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.173 by $0.113.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is -$0.08.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 206,885,940 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.173. Following the earnings report the stock price went up 6.98%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Among the largest hedge funds holding Biocryst Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Biocryst Pharmaceuticals’s shares valued at 50M.
---
BioCryst Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.33 (88.10% Upside)
$15.33 (88.10% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 95%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 7.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $54.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.84%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
---
BCRX Company Deck
---
BCRX Earnings Call
Q2 2024
0:00 / 0:00
---
BCRX Stock 12 Month Forecast
Average Price Target
$15.33
▲(88.10% Upside)
Technical Analysis
Best Analysts Covering BCRX
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+50.81%
reiterated a buy rating 2 months ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +50.81% per trade.
---